Y Intercept Hong Kong Ltd Purchases Shares of 17,833 Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Points

• Y Intercept Hong Kong Ltd acquired 17,833 shares of Janux Therapeutics, valued at approximately $481,000, signaling increased institutional interest in the biotech company.
• Multiple hedge funds significantly increased their stakes in Janux Therapeutics during the 4th quarter, with Price T Rowe Associates Inc. raising their holdings by 596.3%.
• Janux Therapeutics reported an EPS of ($0.38) for its latest quarter, exceeding consensus estimates, and analysts estimate a target price of $91.89 for the stock.

Y Intercept Hong Kong Ltd acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 17,833 shares of the company's stock, valued at approximately $481,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JANX. Russell Investments Group Ltd. boosted its position in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the last quarter. Avanza Fonder AB lifted its stake in Janux Therapeutics by 17.0% during the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company's stock valued at $86,000 after acquiring an additional 444 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Janux Therapeutics by 3.0% during the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company's stock worth $444,000 after acquiring an additional 471 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in Janux Therapeutics by 20.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company's stock worth $109,000 after acquiring an additional 686 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Janux Therapeutics by 6.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,855 shares of the company's stock worth $320,000 after acquiring an additional 727 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Stock Performance

JANX stock traded up $0.14 during mid-day trading on Wednesday, hitting $24.31. The company had a trading volume of 282,171 shares, compared to its average volume of 943,652. The firm has a market cap of $1.44 billion, a PE ratio of -17.98 and a beta of 2.86. Janux Therapeutics, Inc. has a 12 month low of $22.48 and a 12 month high of $71.71. The stock's fifty day moving average price is $24.80 and its two-hundred day moving average price is $30.00.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.05. Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the transaction, the insider directly owned 82,139 shares in the company, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 29.40% of the company's stock.

Wall Street Analyst Weigh In

Separately, Raymond James Financial assumed coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They set an "outperform" rating and a $65.00 price target on the stock. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics has a consensus rating of "Buy" and a consensus target price of $91.89.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.